Meta-analysis results of different anti-VEGF versus PDT treatment for myopia CNV.




Figure 1 Forest plot of studies examining the mean change in BCVA (logMAR).

	Favours [experimental]			Control				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
2.1.1 Ranibizumab thrapy vs PDT									
BRILLIANCE 2019	-71.2	81.28	184	-29.1	75.57	91	75.4%	-42.10 [-61.57, -22.63]	
RADANCE 2014	-77.6	110.67	116	-12	103.85	55	24.6%	-65.60 [-99.64, -31.56]	
Subtotal (95% CI)			300			146	100.0%	-47.89 [-64.79, -30.99]	◆
Heterogeneity: Chi ² =	1.38, df = 1	(P = 0.24)); I ² = 28 ⁴	λ					
Test for overall effect	Z = 5.55 (P	< 0.0000	1)						
2.1.2 Bevacizumab t	hrapy vs P[от							_
Moreno 2013	-50.4	65.72	22	-25.5	64.42	20	100.0%	-24.90 [-64.29, 14.49]	
Subtotal (95% CI)			22			20	100.0 %	-24.90 [-64.29, 14.49]	
Heterogeneity: Not ap	oplicable								
Test for overall effect:	Z=1.24 (P	9 = 0.22)							
									-100 -50 0 50 100
									Favours [experimental] Favours [control]
									ravours texperimental ravours (control)

Figure 2 Forest plot of studies examining the mean change in CFT.

	Experimental Control		ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
3.1.1 Ranibizumab t	hrapy vs Pl	DT					
BRILLIANCE 2019	59	184	15	91	64.9%	1.95 [1.17, 3.23]	-₩-
RADANCE 2014	50	116	8	55	35.1%	2.96 [1.51, 5.81]	
Subtotal (95% CI)		300		146	100.0%	2.30 [1.54, 3.45]	\bullet
Total events	109		23				
Heterogeneity: Chi ² =	= 0.96, df = 1	1 (P = 0	.33); I² =	0%			
Test for overall effect	t: Z = 4.04 (f	P < 0.00	101)				
3.1.2 Bevacizumab t	thrapy vs P	DT					
Moreno 2013	10	22	4	20	80.3%	2.27 [0.85, 6.11]	
Parodi 2010	7	19	1	18	19.7%	6.63 [0.90, 48.69]	
Subtotal (95% CI)		41		38	100.0 %	3.13 [1.29, 7.59]	\bullet
Total events	17		5				
Heterogeneity: Chi ² =	= 0.95, df = 1	1 (P = 0	.33); I ² =	0%			
Test for overall effect	t: Z = 2.53 (F	P = 0.01)				
							0.01 0.1 1 10 100
							Favours [experimental] Favours [control]

Figure 3 Forest plot of studies examining the number of patients who gained more than 3 lines in BCVA.




Figure 4 Forest plot of studies examining the serious ocular adverse events.




Figure 5 Forest plot of studies examining the non-serious ocular adverse events.